Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: Results of a randomised phase III trial (OSHO# 19)

Journal of Cancer Research and Clinical Oncology

Volumn 132, Issue 2, 2006, Pages 105-112

  Herold, M ^a   Schulze, A ^a   Niederwieser, D ^b   Franke, A ^c   Fricke, H J ^d   Richter, P ^e   Freund, M ^f   Ismer, B ^e   Dachselt, K ^g   Boewer, C ^h   Schirmer, V ^e   Weniger, J ⁱ   Pasold, R ^j   Winkelmann C Klinkenstein, C ^e,k   Schulze, M ^l   Arzberger, H ^m   Bremer, K ⁿ   Hahnfeld, S ^o   Schwarzer, A ^p   Muller C ^e   Muller Chr ^q   more..

^a HELIOS KLINIKUM ERFURT   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^c UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e St Hedwig Krankenhaus ^*  (Germany)

^f ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^g Südharz Hospital   (Germany)

^h MARTIN LUTHER KRANKENHAUS   (Germany)

ⁱ Gemeinschaftspraxis Hämatologie Onkologie   (Germany)

^j KLINIKUM ERNST VON BERGMANN   (Germany)

^k Medizinisches Zentrum   (Germany)

^l Bezirkskrankenhaus   (Germany)

^m Gemeinschaftspraxis Hämatologie Onkologie   (Germany)

ⁿ Augusta Kranken Anstalt   (Germany)

^o Gemeinschaftspraxis Hämatologie Onkologie   (Germany)

^p Gemeinschaftspraxis Hämatologie Internistische Onkologie   (Germany)

^q Katholisches Krankenhaus   (Germany)

more..

Author keywords

Bendamustine; Cyclophosphamide; Indolent non Hodgkin's lymphoma; Mantle cell lymphoma; Prednisone; Vincristine

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; CHLORMETHINE DERIVATIVE; COP PROTOCOL 2; CYCLOPHOSPHAMIDE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; LYMPHOCYTOMA; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; MORTALITY; NONHODGKIN LYMPHOMA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; LYMPHOMA, SMALL LYMPHOCYTIC; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; PREDNISONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 33646986211     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-005-0023-2     Document Type: Article

References (26)

1. Bagley CM, Devita VT, Berard CW, Canellos GP (1972) Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med 76(2):227-234
2. Blumenstengel K, Fricke H-J, Kath R, Höffken K (1999) Bendamustine(B), vincristine(O), prednisolone(P) in relapsed and refractory low-grade non-Hodgkin's lymphomas (NHL). Ann Hematol 77(Suppl 2):149 (Abstr 591)
3. Bremer K (2002) High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphomas. J Cancer Res Clin Oncol 128(11):603-609
4. Bremer K, Roth W (1996) Bendamustine, a low toxic nitrogen-mustard derivative with high efficacy in malignant lymphomas. Tumordiagn u Ther 17:1-6 (Pubitemid 26124745)
5. Chow KU, Nowak D, Boehrer S, Ruthardt M, Knau A, Hoelzer D, Mitrou PS, Weidmann E (2003) Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol 66(5):711-724 (Pubitemid 37011409)
6. Dixon DO, McLaughlin P, Hagemeister FB, Freireich EJ, Fuller LM, Cabanillas FF, Gehan EA (1987) Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol 5(10):1670-1672
7. Harris NL, Jaffe ES, Stein H (1994) A revised European-American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group. Blood 84(5):1361-1392 (Pubitemid 24273002)
8. Heider A, Niederle N (2001) Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 12(9):725-729 (Pubitemid 33001185)
9. Herold M, Pasold R, Srock S, Neser S, Niederwieser D, Neubauer A, Dölken G, Naumann R, Fietz T, Freund M, Rohrberg R, Hoeffken K, Franke A, Ittel TH, Kettner E, Haak U, Mey U, Klinkenstein U, Assmann M, von Gruenhagen U, Dachselt K, Schwenke H, Bleyl D, Wolf H, Hahnfeld S, Hoffmann F-A, Lakner V, Richter P, Hähling D, Wolf HH, Eschenburg H, Clemens M-R, Grobe N (2004) Results of a prospective randomised open label phase iii study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (RMCP) versus MCP alone in untreated advanced indolent nonhodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood 104(11):169a (Abstr 584)
10. Hiddemann W, Schmoll H-J, Theml H, Hoffmann W (1999) Follikuläres Keimzentrumslymphom (zentroblastisch-zentrozystisches Lymphom). In: Schmoll, Höffken, Possinger (eds) Kompendium Internistische Onkologie, 3rd edn. Springer, Berlin, Heidelberg, New York, pp 279-296
11. Hiddemann W, Forstpointner R, Kneba M, Schmitz N, Schmits R, Metzner B, Reiser M, Lengfelder E, Woermann B, Harder H, Hegewisch-Becker S, Bredel W, Hess G, Eimermacher H, Aldaoud A, Planker M, Rarwaresch R, Dreyling M, Unterhalt M (2004) The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymphoma but not in mantle cell lymphoma: results of two prospective randomized studies of the German Low Grade Lymphoma Study Group (GLSG) 104(11):50a (Abstr 161)
12. Karnekal S, Crain B, Elliott G, Singh S (2004) SDX-105 (Bendamustine) Inhibits Growth of SU-DHL-1 and Daudi lymphoma xenografts in SCID Mice. PROC AACR 45 (Abstr 4575)
13. Lennert K, Feller AC (1990) In: Histopathologie der non-Hodgkinlymphome (nach der aktualisierten Kiel-Klassifikation), 2nd edn. Springer, Berlin, Heidelberg, New York, p 15
14. Leoni LM, Bailey B, Reifert J (2003) SDX-105 (Bendamustine), a clinically active antineoplastic agent possesses a unique mechanism of action. Blood 102(11):640a (Abstr 2363)
15. Leoni LM, Bailey B, Reifert J, Niemeyer C, Bendall H, Dauffenbach L, Kerfoot C (2004) In vitro and ex vivo activity of SDX-105 (Bendamustine) in drug-resistant lymphoma cells. PROC AACR 45 (Abstr 1215)
16. Niemeyer C, Bailey B, Reifert J, Bendall H, Corbeil J, Leoni LM (2004) SDX-105 (Bendamustine) is a clinically active chemotherapeutic agent with a distinct mechanism of action. PROC AACR 45 (Abstr 1129)
17. Pötscher C, Hiller E, Busch M, Unterhalt M, Hiddemann W (2000) Aktuelle Therapiekonzepte follikulärer Lymphome (zen-troblastisch-zentrozytisch). Akt Onkol 109:3-20
18. Ruffert K (1999) Therapy of low grade non-Hodgkin's-lymphoma (NHL) with bendamustine and oral etoposide. Ann Oncol 10(Suppl 3):125 (Abstr 452)
19. Ruffert K, Jahn H, Syrbe G, Stauch M, Jorke D, Kühn R (1989) Cytostasan (Bendamustin) in der Alternativtherapie maligner Non-Hodgkin-Lymphome. Z Klin Med 44(8):671-674 (Pubitemid 19112259)
20. Rummel M-J, Al-Bartran S, Welslau M, Kofahl-Krause D, Duerk H, Hoelzer D, Mitrou PS (2005) Bendamustine and rituximab act synergistically in vitro and are effective in the treatment of relapsed or refractory indolent and mantle cell lymphomas. J Clin Oncol 23(16S):576s (Abstr 6565)
21. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S (1996) Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7(4):415-421 (Pubitemid 26249195)
22. Unterhalt M, Hermann R, Koch P, Trümper L, Bodenstein H, Dietzfelbinger H, Landys K, Reuß M, Vetter H, Maschmeyer G, Freund M, Neubauer A, Engert A, Stauder R, Herold M, Tiemann M, Parwaresch R, Stein H, Hiddemann W (1996) Long term interferon alpha maintenance prolongs remission duration in advanced low grade lymphomas and is related to the efficacy of initial cytoreductive chemotherapy. Blood 88(Suppl 1):453a (Abstr 1801)
23. Vose JM (1998) Current approaches to the management of non Hodgkin's lymphoma. Semin Oncol 25(4):483-491
24. Vose, JM (1999) Mantle cell lymphoma. In: Non-Hodgkin's lymphoma: treatment for the millenium. Proceedings of a symposium at the 41st annual meeting of the American Society of Hematology, New Orleans
25. Weide R, Pandorf A, Heymanns J, Köppler H (2004) Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 45(12):2445-2449 (Pubitemid 40081187)
26. Weissinger F, Kreipe HH, Wilhelm M (1997) Non hodgkin lymphome. Internist 38:1131-1142